Physician profile
Matthew Chase Cates
NPI 1295189330
$247,589.18
in general payments reported to CMS, 2019-2025
26 companies · $136K in 2025
The $136K reported for 2025 was more than what 99% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $248 · 2020: $223 · 2021: $1,498 · 2022: $9,030 · 2023: $35K · 2024: $66K · 2025: $136K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $165K · Travel and Lodging: $42K · Food and Beverage: $16K · Consulting Fee: $14K.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $164,775.00 |
| Travel and Lodging | $41,912.25 |
| Food and Beverage | $15,933.12 |
| Consulting Fee | $13,970.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Viiv Healthcare Company | $224,211.34 | 2019-2025 | Cabenuva, Dovato, Apretude |
| Gilead Sciences, INC. | $18,810.69 | 2020-2025 | Yeztugo, Biktarvy, Descovy |
| Emd Serono, INC. | $855.70 | 2020-2025 | Serostim, Serostim |
| Merck Sharp & Dohme LLC | $644.98 | 2021-2025 | Pifeltro, Delstrigo, Capvaxive |
| Abbvie INC. | $565.24 | 2021-2025 | Mavyret |
| Janssen Biotech, INC. | $524.22 | 2020-2023 | Symtuza |
| Novo Nordisk INC | $355.79 | 2022-2025 | Rybelsus, Ozempic, Wegovy |
| Theratechnologies INC. | $293.28 | 2020-2025 | Egrifta, Trogarzo |
| Pfizer INC. | $263.65 | 2024-2025 | |
| Axsome Therapeutics, INC. | $185.59 | 2024-2025 | Auvelity |
| Janssen Products, Lp | $125.00 | 2023 | Symtuza |
| Regeneron Healthcare Solutions, INC. | $123.17 | 2019 | |
| Lilly USA, LLC | $87.66 | 2024-2025 | Zepbound, Jardiance, Mounjaro |
| Astrazeneca Pharmaceuticals Lp | $74.31 | 2024-2025 | Airsupra |
| Napo Pharmaceuticals INC | $73.18 | 2023-2025 | Mytesi |
Show all 26 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Takeda Pharmaceuticals U.S.A., INC. | $66.61 | 2024 | Trintellix |
| Antares Pharma, INC. | $61.65 | 2024-2025 | Xyosted |
| Biohaven Pharmaceutical Holding Company Ltd. | $45.08 | 2022 | |
| Halozyme INC | $38.42 | 2023 | |
| Otsuka America Pharmaceutical, INC. | $36.16 | 2025 | Rexulti |
| Acerus Pharmaceuticals Corporation | $29.36 | 2022 | |
| Dynavax Technologies Corporation | $29.22 | 2023-2025 | Heplisav-B |
| Janssen Pharmaceuticals, INC | $28.48 | 2021 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $25.17 | 2025 | Caplyta |
| Exeltis, USA INC. | $20.28 | 2023 | Slynd |
| Tolmar, INC. | $14.95 | 2023 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Matthew Cates listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.